Drug Trial Radar · NCT05163028
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Dec 13, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- HUYABIO International, LLC.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Conditions
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Solid Tumor
- Cancer
- Cancer of Pancreas
- Cancer of Colon
Interventions
HBI-2376Drug
SHP2 Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.Time frame: Up to 36 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
California Cancer Associates for Research and Excellence, Inc. (cCare)
Encinitas, California
Providence Medical Foundation
Fullerton, California
California Cancer Associates for Research and Excellence, Inc. (cCare)
San Marcos, California
Sarcoma Oncology
Santa Monica, California
UCLA Hematology/Oncology
Santa Monica, California
Orlando Health, Inc.
Orlando, Florida
BRCR Medical Center
Plantation, Florida
Gabrail Cancer Center
Canton, Ohio
Texas Oncology - Tyler
Tyler, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Pan American Center for Oncology Trials (PanOncology Trials)
Rio Piedras, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.